evipedia.ai
← Back

Enclomiphene to Improve Testosterone

Evidence Review created on 10/29/2026 using AI4L / Opus 5.5

Also known as: Enclomifene, Enclomiphene Citrate, trans-Clomiphene, (E)-Clomiphene, Androxal, EnCyzix

Motivation

Enclomiphene is an oral medication that blocks estrogen’s braking signal in the brain, which prompts the testes to make more of their own testosterone. It is one of the two chemical forms that together make up clomiphene, a long-established fertility drug. Interest comes from men with low testosterone who want higher levels without the shutdown of natural hormone and sperm production that comes with taking testosterone itself.

Clomiphene has been given to men outside its approved use for decades. Enclomiphene was developed as a purer version and studied in company-run trials, but it was refused approval in Europe and never approved in the United States. It now reaches men mainly through pharmacies that prepare custom medications and through online men’s-health services, which has drawn attention from clinicians, regulators and people focused on long-term health.

This review examines the human evidence on enclomiphene’s effects on testosterone, sperm production, symptoms and safety; how it compares with clomiphene and with testosterone itself; and the practical questions of dosing, monitoring and sourcing it raises for health-focused men.

Benefits - Risks - Protocol - Conclusion

Expert commentary and reviews discussing enclomiphene for secondary hypogonadism (low testosterone caused by weak pituitary signaling to otherwise healthy testes), or the clomiphene drug class it belongs to, in depth.

No enclomiphene content was found from Chris Kresser or Lifespan.io on web or on-site search. Rhonda Patrick’s FoundMyFitness has one episode that touches on enclomiphene only in passing (FoundMyFitness #106), with the same guest as the Peter Attia item (Derek, More Plates More Dates), so it was not listed.

Grokipedia

Enclomifene

An AI-generated encyclopedia entry covering mechanism, dosing, adverse effects, drug interactions, regulatory history and the relation to clomiphene; useful as a structured overview, though its claims need checking against primary sources.

Examine

No Examine.com article on enclomiphene exists. Examine.com does not typically cover prescription medications, and enclomiphene is available only by prescription (as a compounded, unapproved drug) (Foster 2026).

ConsumerLab

No ConsumerLab.com article on enclomiphene exists. ConsumerLab does not typically cover prescription medications, and enclomiphene is available only by prescription (Foster 2026).

Systematic Reviews

Systematic reviews and meta-analyses (studies that pool the results of many trials) on enclomiphene, or on its parent mixture clomiphene, in men with low testosterone.

No systematic review addresses enclomiphene-specific harms such as blood clots; the risk review listed concerns clomiphene alone.

Mechanism of Action

Enclomiphene is the trans-isomer (one of two geometric forms of the same molecule) of clomiphene and a selective estrogen receptor modulator (SERM, a drug that blocks estrogen in some tissues and mimics it in others). In men, estradiol made from testosterone acts on hypothalamic and pituitary estrogen receptors to restrain hormone output (negative feedback).

  • Central estrogen blockade: Enclomiphene occupies these receptors, so the brain raises gonadotropin-releasing hormone (GnRH, the hypothalamic trigger signal), luteinizing hormone (LH, which drives testosterone production in the testes’ Leydig cells) and follicle-stimulating hormone (FSH, which supports sperm production) (Wiehle 2013, a trial run by the manufacturer, Repros Therapeutics).
  • Restoration, not replacement: The hypothalamic-pituitary-gonadal (HPG) axis (the brain-to-testes hormone loop) stays active, whereas external testosterone suppresses LH and FSH.
  • Isomer selectivity: Zuclomiphene, clomiphene’s other isomer, is more estrogen-like and lingers for weeks; enclomiphene is the more purely anti-estrogenic form (Rodriguez 2016).
  • Pharmacokinetics: Blood levels peak 2–3 hours after dosing; half-life is about 7 hours, with some accumulation on daily dosing (Wiehle 2013).
  • Distribution: Human tissue data are lacking; effects on rat bone (Turner 1998) show action beyond the brain.
  • Metabolism: CYP2D6 (a liver enzyme that processes many drugs) forms potent 4-hydroxylated active metabolites, and CYP3A4 (another major drug-processing liver enzyme) also contributes (Mürdter 2012, Kovar 2022).
  • Competing view: Body-wide estrogen blockade may blunt estrogen’s roles in bone and libido even as blood estradiol rises; enclomiphene lowered insulin-like growth factor 1 (IGF-1, a growth-hormone marker) (Wiehle 2013).

Historical Context & Evolution

Clomiphene has been used since the 1960s to induce ovulation in women, and clinicians began using it off-label (outside its approved indication) to raise testosterone and sperm counts in men (Rodriguez 2016). Because zuclomiphene appeared responsible for lingering estrogen-like effects, Repros Therapeutics developed purified enclomiphene, branded Androxal, for secondary hypogonadism (Hill 2009).

Repros-sponsored trials published from 2013 to 2016 found that enclomiphene restored testosterone and maintained sperm counts, while testosterone gel suppressed them (Kim 2016, sponsored by Repros). The FDA, however, did not accept a testosterone rise alone as evidence of benefit for a non-testosterone drug, and a 2015 meeting to review the application was cancelled over concerns about the validation of the laboratory method (Rodriguez 2016). In 2018 the European Medicines Agency (EMA) refused authorization of the brand EnCyzix, citing untested symptom benefits and a risk of venous thromboembolism (blood clots in the veins) (EMA EnCyzix assessment). Development was discontinued in 2021 (Foster 2026).

Use then shifted to compounding pharmacies and telehealth services, and in June 2022 the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed whether pharmacies may compound enclomiphene from bulk substance and voted against adding it to the 503A bulks list, per the minutes posted on the meeting page (FDA PCAC June 2022 meeting). What changed over time was less the testosterone data, which independent retrospective series later echoed (Saffati 2024), than regulators’ demand for symptom, fertility and long-term safety outcomes that no trial has yet supplied.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every randomized enclomiphene trial comes from one sponsor’s program (Repros), and the independent data are retrospective cohorts or indirect clomiphene trials.

Medium 🟩 🟩

Restores Testosterone Through the Body’s Own Production

In men with secondary hypogonadism, enclomiphene raises morning total testosterone into the normal range by increasing LH and FSH, whereas testosterone gel suppresses them. Randomized trials led by Kaminetsky (Kaminetsky 2013), Wiehle (Wiehle 2014) and Kim (Kim 2016), all sponsored by Repros, showed this, and an independent meta-analysis of randomized trials confirmed it (Hohl 2025). Independent cohorts from Baylor and Miami report similar rises (Saffati 2024, Thomas 2023). Gains are smaller with older age and higher body mass.

Magnitude: Clomiphene or enclomiphene raised total testosterone 273.76 ng/dL more than placebo (95% CI, confidence interval, the range likely to contain the true effect: 191.87–355.66) in pooled randomized trials (Hohl 2025); enclomiphene alone raised it 7.50 nmol/L from baseline (95% CI 6.52–8.48; no control group) (Tienforti 2023).

Preserves Sperm Production Compared With Testosterone Therapy ⭕️ Not Central to Improve Testosterone

This bears on fertility rather than on the testosterone level itself. Because FSH and LH rise, sperm output is maintained, whereas testosterone gel suppressed it in randomized trials led by Kaminetsky (Kaminetsky 2013), Wiehle (Wiehle 2014) and Kim (Kim 2016). An independent meta-analysis found a larger sperm-concentration change than with testosterone gel but no difference from placebo (Hohl 2025). A minority of men still show falling counts (see Risks).

Magnitude: At 3 months, all 7 enclomiphene-treated men had sperm concentrations of 75–334 million/mL, while none of 5 gel-treated men exceeded 20 million/mL; not compared between groups (Kaminetsky 2013).

Low 🟩

Fewer Side Effects Than Clomiphene ⭕️ Not Central to Improve Testosterone

This bears on tolerability rather than on the testosterone level. In a Baylor cohort of 66 men switched from clomiphene to enclomiphene, decreased libido, low energy and mood changes were less frequent on enclomiphene (Saffati 2024). This single retrospective, sequential comparison may favor the second drug; no randomized trial exists.

Magnitude: Odds of adverse events were lower on enclomiphene than on clomiphene (OR, odds ratio, the relative odds of an event between groups: 0.18; 95% CI 0.07–0.44) (Saffati 2024); the British Society for Sexual Medicine (BSSM) statement, whose members and telehealth-affiliated authors earn from this care, reports side-effect rates of 13.8% versus 47% for this cohort (Foster 2026).

Relief of Low-Testosterone Symptoms ⭕️ Not Central to Improve Testosterone

This bears on symptoms such as libido and energy, not the testosterone level. No enclomiphene trial used a validated symptom scale, a gap the EMA cited (EMA EnCyzix assessment). Evidence is indirect, from clomiphene: symptom scores improved (Huijben 2022), yet libido trailed testosterone therapy (Constantinou 2026).

Magnitude: For clomiphene, post-treatment libido scores on the Androgen Deficiency in the Aging Male (ADAM) questionnaire item were 0.54 points lower than with testosterone therapy (95% CI −0.87 to −0.21) (Constantinou 2026); no enclomiphene figure exists.

Lower Erythrocytosis Risk Than Testosterone Therapy ⭕️ Not Central to Improve Testosterone

This bears on blood safety: erythrocytosis (polycythemia, an excess of red blood cells that thickens the blood). Evidence is indirect, from clomiphene: in a multi-institution retrospective comparison it was far less common than with testosterone therapy (Wheeler 2017). Enclomiphene-specific data are unpublished.

Magnitude: Polycythemia prevalence was 1.7% with clomiphene versus 11.2% with testosterone therapy (p, the probability that a difference this large arises by chance, = 0.0003) (Wheeler 2017).

Body Composition ⭕️ Not Central to Improve Testosterone ⚠️ Conflicted

This bears on lean mass and fat. A placebo-controlled clomiphene trial increased lean mass in obese men (Soares 2018), but that evidence is indirect. The only enclomiphene trial, with diet and exercise (NCT02651688), posted no significant lean-mass or strength difference from placebo. Net: no demonstrated enclomiphene effect.

Magnitude: At 48 weeks, lean body mass rose 3.14 kg with enclomiphene 12.5 mg and 2.40 kg with 25 mg versus 1.05 kg with placebo, differences that were not significant (p = 0.71 and p = 0.45) (NCT02651688).

Glycemic Control ⭕️ Not Central to Improve Testosterone ⚠️ Conflicted

Bears on blood sugar. An early review reported a fasting-glucose signal (Hill 2009), but a 3-month trial in men with type 2 diabetes (NCT01191320) posted no HbA1c (average blood sugar over about three months) change, and a class meta-analysis found neutral effects (Hohl 2025). Net: no glycemic benefit is supported.

Magnitude: Mean change in HbA1c was 0 in the 12.5 mg, 25 mg and placebo groups at 3 months (not compared between groups) (NCT01191320).

Speculative 🟨

Bone Preservation ⭕️ Not Central to Improve Testosterone

This bears on bone. In estrogen-deficient rats, enclomiphene’s bone effects resembled clomiphene’s (Turner 1998). A human bone-density trial (NCT01619683) posted no results; the basis is animal and mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: CYP2D6 variants change formation of the active metabolites; women with non-functional CYP2D6 alleles had 8–12 times lower peak levels of active metabolites (Mürdter 2012), while CYP2D6*10 homozygotes had higher active exposure (Kim 2018). Effects on male testosterone response are untested.
  • Baseline LH and testosterone: Benefit needs a working pituitary-testis loop; raised LH signals testicular failure (primary hypogonadism), where BSSM, whose members and telehealth-affiliated authors earn from this care, notes limited success (Foster 2026). Trials enrolled men with testosterone at or below 300 ng/dL (Kim 2016).
  • Sex: All testosterone data come from men. In women, the parent drug clomiphene is used to induce ovulation; testosterone-raising use in women has not been studied.
  • Pre-existing conditions: Testosterone gains were smaller with higher body mass index (Hohl 2025), although one meta-analysis found the strongest clomiphene response in severely obese men (Tienforti 2023). Steroid-induced suppression is another common use.
  • Age: Testosterone gains shrink with advancing age (Hohl 2025). Phase III efficacy trials enrolled men aged 18–60 (Kim 2016); a phase II trial (Wiehle 2013) and the safety study (NCT01534208) admitted men to 65, and a diabetes trial (NCT01191320) to 80, without age-specific results.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: enclomiphene’s adverse-event data come from manufacturer-run trials of up to one year, and no harm has been replicated in an independent randomized trial.

Medium 🟥 🟥

Falling Sperm Counts in a Subset ⚠️ Conflicted

Although average sperm concentration is maintained, some men show large declines. In two Repros phase III trials, more enclomiphene-treated than placebo-treated men had sperm concentration fall by half or more within 3 months (NCT01532414, NCT01739595). The same paradox occurs with clomiphene, sometimes persisting after stopping (Gundewar 2021). By contrast, Kim’s phase III report found mean concentrations kept in the normal range (Kim 2016). Net: average preservation coexists with a minority whose counts fall.

Magnitude: A 50% or greater drop in sperm concentration occurred in 14.2% of enclomiphene-treated men versus 2.6% on placebo (NCT01532414) and 14.2% versus 4.3% (NCT01739595).

Smaller Weight Loss During Dieting

In the only enclomiphene trial that paired treatment with a commercial diet plan and supervised exercise (NCT02651688), men on enclomiphene lost significantly less weight and body mass index than men on placebo over 48 weeks. The mechanism is unknown, the placebo group started heavier, and the manufacturer, Repros, posted the results only on ClinicalTrials.gov. Outside a diet program, a meta-analysis of randomized trials found neutral effects on body mass index (Hohl 2025).

Magnitude: At 48 weeks, weight fell 4.36 kg with enclomiphene 12.5 mg and 6.15 kg with 25 mg versus 14.51 kg with placebo (p = 0.0139 and p = 0.0225) (NCT02651688).

Low 🟥

Venous Thromboembolism

The EMA cited a clot risk when refusing authorization (EMA EnCyzix assessment). The open-label safety study recorded deep vein thrombosis (a clot in a deep leg vein) and pulmonary embolism (a clot lodged in the lung arteries) (NCT01534208). A clomiphene cohort found few clots (Kavoussi 2019).

Magnitude: 2 deep vein thromboses and 1 pulmonary embolism among 490 enclomiphene-treated men, no control group (NCT01534208); 1 deep vein thrombosis among 486 clomiphene users versus 9 among 694 on testosterone therapy (Kavoussi 2019).

Visual Disturbances

Blurring, spots or flashes (scintillating scotomata, flickering blind spots). The clomiphene label warns they rise with dose and duration and may rarely persist (clomiphene label (Drugs.com)). Evidence is indirect, from clomiphene; enclomiphene-specific rates are unreported (Krzastek 2019).

Magnitude: Blurred vision in 3 of 120 men treated with clomiphene for more than 3 years, no control group (Krzastek 2019).

Enclomiphene raises estradiol along with testosterone (Wiehle 2014). The clomiphene label notes gynecomastia (enlarged male breast tissue) in men (clomiphene label (Drugs.com)). After switching from clomiphene, estradiol fell slightly on enclomiphene (Saffati 2024).

Magnitude: Breast tenderness in 2 of 120 long-term clomiphene users, no control group (Krzastek 2019); estradiol changed −5.92 pg/mL on enclomiphene versus +17.50 pg/mL on clomiphene (p = 0.001) (Saffati 2024).

Mood Changes

Anxiety, irritability or low mood. Reported with clomiphene in a case report (Aussedat 2017) and in long-term users (Krzastek 2019); after switching to enclomiphene, mood changes were less frequent (Saffati 2024).

Magnitude: Mood changes in 5 of 120 men treated with clomiphene for more than 3 years, no control group (Krzastek 2019); enclomiphene rates are not reported separately.

Common Mild Adverse Events

Headache, hot flushes, muscle spasms and dizziness were the most frequent drug-type events in the 6-month open-label safety study (NCT01534208); the BSSM, whose members and telehealth-affiliated authors earn from this care, lists similar low rates (Foster 2026). Most are mild; 23 of 499 men withdrew for adverse events.

Magnitude: Headache in 12 of 207 (12.5 mg) and 23 of 283 (25 mg); hot flush in 2 of 207 and 9 of 283; muscle spasms in 10 of 207 and 12 of 283; no control group (NCT01534208).

Testicular Tumors

The clomiphene label notes testicular tumor reports in men, causality unknown (clomiphene label (Drugs.com)). A 1985 clomiphene series (Nilsson 1985) and the enclomiphene safety study, with one seminoma (a testicular germ-cell cancer) (NCT01534208), recorded cases.

Magnitude: 2 testicular tumors among 650 men given clomiphene for 6–12 months, no control group (Nilsson 1985); 1 seminoma among 490 enclomiphene-treated men, no control group (NCT01534208).

Heart Rhythm Disturbance

Atrial flutter (a fast, abnormal rhythm of the heart’s upper chambers) appeared after an accidental dose doubling in a man with prior valve surgery; causality was rated only possible (Tariq 2026). One case occurred in the safety study (NCT01534208).

Magnitude: 1 atrial flutter among 283 men on 25 mg, no control group (NCT01534208); otherwise only a single case report exists.

Stroke and Seizure

Stroke and seizure appear in clomiphene post-marketing reports, causality unestablished (clomiphene label (Drugs.com)). The enclomiphene safety study recorded one transient ischemic attack (a brief, stroke-like interruption of brain blood flow) (NCT01534208). Evidence is indirect or uncontrolled; a veterans cohort found fewer strokes with clomiphene than with testosterone therapy (Tadisina 2026).

Magnitude: 1 transient ischemic attack among 207 men on 12.5 mg, no control group (NCT01534208); strokes in 0.52% of clomiphene users versus 1.43% on testosterone therapy (Tadisina 2026).

Hypertriglyceridemia and Pancreatitis

Hypertriglyceridemia (very high blood triglyceride fats), sometimes causing pancreatitis (inflammation of the pancreas), is a clomiphene label warning, chiefly with pre-existing lipid disorders (clomiphene label (Drugs.com)). A case report describes it in a woman (Castro 1999). Evidence is indirect, from clomiphene; no enclomiphene cases are reported.

Magnitude: Not quantified in available studies. Only post-marketing and case reports exist, with no comparison group.

Liver Injury ⚠️ Conflicted

Hepatitis (liver inflammation) and raised liver enzymes appear in clomiphene post-marketing reports (clomiphene label (Drugs.com)); a man developed reversible liver injury after 5 days (Zhang 2018). Evidence is indirect, from clomiphene. A randomized trial in women found liver enzymes fell slightly (Aubuchon 2011). Net: injury appears rare, without average harm.

Magnitude: 1 case of liver injury in a man, no control group (Zhang 2018); in 209 women on clomiphene, transaminases (liver enzymes) fell 9–11% from baseline versus no significant change with metformin, not compared between groups (Aubuchon 2011).

Speculative 🟨

Lowered IGF-1

Enclomiphene lowered IGF-1 more than testosterone gel, within the normal range (Wiehle 2013). IGF-1 here is an unvalidated marker; any clinical consequence is mechanistic speculation.

Long-Term Estrogen-Receptor Blockade

Years of estrogen-receptor blockade could affect bone, lipids or brain function. No enclomiphene data beyond about one year exist; the concern is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP2D6*10 homozygotes had about two- to threefold higher active clomiphene exposure (Kim 2018), possibly raising side-effect risk. Inherited clotting disorders such as factor V Leiden plausibly add to the clot signal (inferred, no data).
  • Baseline biomarkers: Low baseline sperm counts make a paradoxical decline more consequential. Higher baseline hematocrit, estradiol or liver enzymes narrow safety margins, and closer monitoring is common practice in these men.
  • Sex: Men face male-specific risks (gynecomastia, testicular findings); women taking clomiphene face ovarian hyperstimulation instead (clomiphene label (Drugs.com)).
  • Pre-existing conditions: Prior clots, liver disease, lipid disorders, visual disorders, mood disorders and structural heart disease (Tariq 2026) raise the stakes of the corresponding risks.
  • Age: Clot and prostate-cancer risk rise with age, and most trials excluded men over 60 (Kim 2016), so older men’s risks are less characterized.

Key Interactions & Contraindications

Documented interactions:

  • CYP2D6 inhibitors (drugs blocking the CYP2D6 enzyme; paroxetine, fluoxetine, bupropion): A pharmacokinetic model checked against human paroxetine data shows altered parent and active-metabolite exposure (Kovar 2022). Consequence: less predictable testosterone response. Mitigation: testosterone is commonly rechecked 4–6 weeks after the inhibitor is started or stopped.
  • Strong CYP3A4 inhibitors (drugs blocking the CYP3A4 enzyme; clarithromycin, itraconazole, ketoconazole): The same model, checked against clarithromycin data, shows altered enclomiphene and metabolite exposure (Kovar 2022). Consequence: unpredictable drug levels and side effects. Mitigation: enclomiphene is commonly paused during short courses, or levels are rechecked.
  • Testosterone therapy and anabolic steroids (synthetic testosterone derivatives; testosterone cypionate, nandrolone): In a Menwell-run telehealth cohort, the parent drug clomiphene plus testosterone lowered FSH, while clomiphene alone raised LH and FSH (Clift 2026). Consequence: lost testicular stimulation. Mitigation: sequential use, checking LH after androgens stop.
  • Human chorionic gonadotropin (hCG): One randomized trial, summarized by a meta-analysis, found similar testosterone with a SERM alone or plus hCG (158 vs 153 ng/dL), not formally compared (Hohl 2025). Consequence: no added gain shown. Mitigation: testosterone is commonly rechecked 4 weeks after combining.
  • Aromatase inhibitors (drugs blocking testosterone-to-estrogen conversion; anastrozole, letrozole): In 51 men, adding anastrozole to the parent drug clomiphene normalized raised estradiol while testosterone held (Alder 2018). Consequence: lower estradiol, with bone and libido effects if overshot. Mitigation: estradiol is commonly measured before adding one.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other estrogen-receptor drugs (tamoxifen, raloxifene, estradiol products): Inferred from competition at the estrogen receptor. Consequence: unpredictable LH and testosterone response. Mitigation: estrogen-receptor drugs are generally not duplicated without specialist input.
  • Over-the-counter CYP2D6 inhibitors (diphenhydramine, cimetidine): Inferred from CYP2D6 inhibition. Consequence: reduced active-metabolite formation and weaker response. Mitigation: testosterone is commonly rechecked if these are used daily.
  • St John’s wort (Hypericum perforatum): Inferred from CYP3A4 induction (enzyme up-regulation). Consequence: lower enclomiphene exposure and weaker effect. Mitigation: regular co-use is commonly avoided, or testosterone rechecked.
  • Testosterone-supporting supplements (DHEA, dehydroepiandrosterone, an adrenal hormone precursor; tongkat ali, Eurycoma longifolia; boron): Inferred from additive effects on testosterone and estradiol. Consequence: higher estradiol or testosterone than intended. Mitigation: supplements are commonly added one at a time, with retesting.
  • Prothrombotic agents (oral estrogens, testosterone with high hematocrit): Inferred from additive clotting tendency (estrogen-driven clotting factors, thicker blood at high hematocrit) on top of enclomiphene’s possible clot risk. Consequence: added venous thromboembolism risk. Mitigation: these are generally not combined in men with prior clots.

Populations who should avoid Enclomiphene:

  • Liver disease or a history of liver dysfunction: Contraindicated on the clomiphene label (clomiphene label (Drugs.com)) and in the BSSM statement, whose members and telehealth-affiliated authors earn from this care (Foster 2026).
  • Uncontrolled thyroid or adrenal dysfunction: Contraindicated on the clomiphene label (clomiphene label (Drugs.com)).
  • Pituitary tumor or other organic intracranial lesion: Contraindicated on the clomiphene label (clomiphene label (Drugs.com)).
  • Known allergy to clomiphene or enclomiphene: Contraindicated on the clomiphene label (clomiphene label (Drugs.com)) and in the BSSM statement, whose members and telehealth-affiliated authors earn from this care (Foster 2026).
  • Primary hypogonadism (testicular failure with raised LH, e.g., Klinefelter syndrome, a genetic extra-X condition): The BSSM, whose members and telehealth-affiliated authors earn from this care, notes limited success (Foster 2026).
  • Prior venous thromboembolism or known clotting disorder: Inferred from the clot risk the EMA cited (EMA EnCyzix assessment); no human data in this group.
  • Men who developed visual symptoms on clomiphene or enclomiphene: The label directs stopping treatment (clomiphene label (Drugs.com)).
  • Athletes subject to anti-doping testing: Clomifene, of which enclomiphene is an isomer, is prohibited at all times under category S4 (hormone and metabolic modulators) (WADA Prohibited List).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Confirmation of secondary hypogonadism: Two morning testosterone measurements plus LH, as in the trials (Kim 2016), prevent treating testicular failure, where enclomiphene does not work.
  • Low starting dose with titration: Beginning at 6.25 mg daily and increasing weekly toward 25 mg, per the BSSM, whose members and telehealth-affiliated authors earn from this care (Foster 2026), limits estrogen-related and mood side effects.
  • Semen analysis when fertility matters: A baseline sample and a repeat at 3 months detect the paradoxical sperm decline seen in about 14% of trial participants (NCT01532414, NCT01739595).
  • Stopping for visual symptoms: Any blurring or flashes mean stopping and prompt eye examination, per the clomiphene label (clomiphene label (Drugs.com)), preventing prolonged visual disturbance.
  • Clot-risk screening: Excluding men with prior clots, and seeking urgent care for leg swelling or sudden breathlessness, mitigates venous thromboembolism.
  • Hematocrit ceiling: Pausing if hematocrit exceeds 54%, the Endocrine Society action threshold for testosterone therapy (Bhasin 2018; its members bill for hormone care whichever agent is used), prevents erythrocytosis-related clotting.
  • Dose reduction for estrogen symptoms: Lowering the dose when breast tenderness appears with rising estradiol mitigates gynecomastia.
  • Licensed pharmacy only: A prescription filled by a licensed pharmacy, never a “research chemical,” mitigates contamination, wrong-isomer content and dosing error.
  • Triglyceride screening: Periodic triglyceride monitoring in men with a personal or family history of lipid disorders, as the clomiphene label recommends (clomiphene label (Drugs.com)), mitigates drug-induced hypertriglyceridemia and pancreatitis.
  • Monthly testicular self-examination: Detects testicular lumps early, given the tumor reports with clomiphene (Nilsson 1985).

Therapeutic Protocol

Timing, titration steps and cycling below reflect common practice unless cited.

  • Phase III regimen: 12.5 mg or 25 mg orally once daily for 16 weeks in Repros-sponsored phase III trials (Kim 2016); phase II tested 6.25–25 mg daily (Wiehle 2013).
  • BSSM titration: Start 6.25 mg daily, increase weekly to 25 mg, and up to 50 mg daily if response is inadequate (Foster 2026); BSSM members bill for such specialist care, and three authors work for a telehealth company.
  • Clinical cohort doses: A Miami cohort (Thomas 2023) used enclomiphene 12.5 mg or 25 mg daily, versus clomiphene 50 mg every other day, as summarized by the BSSM (Foster 2026).
  • Competing approaches: Generic clomiphene (Huijben 2022), testosterone therapy with or without hCG, and hCG alone are alternatives; testosterone therapy gave better libido scores but suppresses sperm (Constantinou 2026).
  • Who popularized it: Developed by Repros Therapeutics; now promoted by telehealth services and discussed by Peter Attia’s guest Derek, More Plates More Dates (Attia podcast #274), and Life Extension (Life Extension protocol).
  • Time of day: Trial participants took enclomiphene in the morning (Wiehle 2013); morning dosing with consistent timing is usual.
  • Half-life: About 7 hours, yet LH and testosterone stay raised for at least a week after stopping (Wiehle 2013), supporting once-daily or less frequent dosing.
  • Single versus split dose: All trials used one daily dose; split dosing has no data. Alternate-day dosing is used in practice without trial support.
  • Genetic polymorphisms: CYP2D6 status may alter active-metabolite levels (Mürdter 2012); no genotype-based dosing guidance exists.
  • Sex: Protocols apply to men only; testosterone-raising use in women is unstudied.
  • Age: Smaller responses with age (Hohl 2025) mean older men more often need the higher dose or an alternative.
  • Baseline biomarkers: Trials required testosterone at or below 300 ng/dL with LH below 9.4 IU/L (Kim 2016); raised LH predicts poor response.
  • Pre-existing conditions: In obesity-related low testosterone, long-term weight loss itself correlates with rising testosterone, as a narrative review notes (Rodriguez 2016), so enclomiphene is commonly paired with weight reduction.

Discontinuation & Cycling

  • Short-term or ongoing: Temporary use until a reversible cause such as obesity resolves may be warranted, per a meta-analysis (Hohl 2025); enclomiphene data beyond one year are absent, though clomiphene has been used for over three years (Krzastek 2019).
  • After stopping: Testosterone stays raised for at least a week (Wiehle 2013) and returns to pre-treatment values within about a month (Kaminetsky 2013).
  • Withdrawal effects: No withdrawal syndrome is described; low-testosterone symptoms simply return as levels fall.
  • Tapering: Trials stopped abruptly; no tapering protocol has been studied or shown necessary.
  • Cycling: No evidence shows cycling maintains efficacy; trial investigators only speculated that intermittent dosing might work (Wiehle 2013).

Sourcing and Quality

  • No approved product: Enclomiphene is approved neither by the FDA nor the EMA (Foster 2026). US supply comes from 503A compounding pharmacies (state-licensed pharmacies preparing drugs for individual prescriptions); in the UK it is unlicensed (Foster 2026).
  • What to look for: A pharmacy licensed in the patient’s state, ideally with Pharmacy Compounding Accreditation Board (PCAB) accreditation, and a certificate of analysis confirming enclomiphene citrate identity, potency and absence of the zuclomiphene isomer.
  • Research-chemical products: Online vendors sell enclomiphene “not for human use”; such products have no pharmaceutical quality control or dose verification.
  • Compounding pharmacies: Large US 503A pharmacies, such as Empower Pharmacy and Strive Pharmacy, supply most telehealth services; no independent quality ranking of their enclomiphene exists, so pharmacy-specific testing documents matter more than brand.
  • Novel formulations: Sublingual mixtures combining enclomiphene with boron and other ingredients rest on an uncontrolled 15-man series (Warren 2026).
  • Approved alternative: Generic clomiphene is an FDA-approved drug, approved for female infertility (Rodriguez 2016), but its tablets contain both isomers, including zuclomiphene.

Practical Considerations

  • Time to effect: Testosterone rises within 2 weeks and plateaus by about 4 weeks (Wiehle 2013); symptom changes have not been measured.
  • Common pitfalls: Using it with raised LH (testicular failure), afternoon testosterone testing, buying research chemicals, combining with testosterone therapy, expecting proven symptom gains, and neglecting weight loss.
  • Regulatory status: Unapproved by the FDA (Foster 2026) and refused by the EMA in 2018 (EMA EnCyzix assessment); an FDA compounding committee voted in June 2022 against adding it to the 503A bulks list (FDA PCAC June 2022 meeting); prohibited in sport (WADA Prohibited List).
  • Cost and payer incentives: Insurance may be more likely to cover generic clomiphene than enclomiphene (Life Extension protocol). Insurers favor cheaper generics, and with no patent holder, no party funds large trials, a structural bias in evidence generation.

Interaction with Foundational Habits

  • Sleep: Indirect. Short or disrupted sleep lowers testosterone and can mask enclomiphene’s effect; enclomiphene itself has no reported sleep disruption. Practical consideration: testing after normal nights, and evaluating snoring or sleep apnea, which also suppresses testosterone.
  • Nutrition: Possible blunting. Weight loss raises testosterone on its own in obesity-related low testosterone, as a narrative review notes (Rodriguez 2016), yet with a diet plan, enclomiphene-treated men lost less weight than placebo (NCT02651688). A food-effect study (NCT02146391) posted no results; consistent dosing relative to meals is common practice.
  • Exercise: None demonstrated. In the 48-week trial combining enclomiphene with diet and exercise, lean mass and strength did not differ from placebo (NCT02651688); no blunting of training adaptations is reported. Resistance training remains the main driver of muscle gain.
  • Stress management: Direct effect none: enclomiphene did not change ACTH (adrenocorticotropic hormone, the pituitary stress signal) or cortisol (Wiehle 2013). Chronic stress lowers testosterone indirectly, and mood changes on treatment are a reported side effect (see Risks).

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes that low testosterone is secondary and records reference values: two early-morning total testosterone measurements, LH and FSH, estradiol, hematocrit, liver enzymes, fasting triglycerides, prostate-specific antigen (PSA) in men over 40, and a semen analysis when fertility matters. A raised LH at baseline points to testicular failure, where enclomiphene is unlikely to help.

Ongoing monitoring follows this cadence: testosterone, LH and estradiol at 4–6 weeks after starting or changing dose; testosterone, estradiol, hematocrit and semen analysis at 3 months; then testosterone, hematocrit, estradiol and PSA every 6–12 months while treatment continues, adding triglycerides with a lipid-disorder history. Success is defined as morning testosterone in the target range with LH and FSH raised from baseline, stable semen measures, and no visual, clotting or mood warning signs.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total testosterone (morning) 450–600 ng/dL (AUA guideline target) Expected to change; defines response Drawn 7–10 a.m.; American Urological Association (AUA) target per Mulhall 2018 (AUA urologists prescribe both testosterone and SERM therapy); conventional reference 264–916 ng/dL (Travison 2017)
LH About 1.7–8.6 IU/L (standard reference range) Expected to change; baseline confirms secondary cause Laboratory-specific; raised baseline LH predicts non-response; LH rises on treatment
FSH About 1.5–12.4 IU/L (standard reference range) Expected to change; sperm-production signal Laboratory-specific; paired with LH
Estradiol About 10–40 pg/mL (standard reference range) Expected to change; safety check for estrogen effects Laboratory-specific; a sensitive LC-MS/MS (liquid chromatography–tandem mass spectrometry) assay is preferred; drawn with testosterone
Hematocrit Below 54% (Endocrine Society action threshold) Safety check; stops or reduces use Threshold from Bhasin 2018 (Endocrine Society members bill for hormone care whichever agent is used); conventional male reference about 40–50%
PSA (men over 40) No established target; track change from own baseline Safety check; prompts urologic review Endocrine Society flags a rise above 1.4 ng/mL within 12 months on testosterone therapy (Bhasin 2018; its members bill for hormone care whichever agent is used)
ALT About 7–56 U/L (standard reference range) Safety check; liver disease contraindicates use ALT: alanine aminotransferase, a liver enzyme; laboratory-specific; contraindication per clomiphene label (Drugs.com)
Triglycerides (fasting) Below 150 mg/dL (standard reference range) Safety check; a marked rise stops use Pretreatment screening per the clomiphene label (Drugs.com), repeated periodically with a personal or family lipid-disorder history; 9–12 hour fast
Semen analysis (if fertility matters) Sperm concentration at least 16 million/mL (standard reference range) Safety check; detects paradoxical decline World Health Organization (WHO) lower reference limit (WHO semen manual, 6th ed.); compared with the man’s own pre-treatment sample; collected after 2–5 days of abstinence; repeated once if abnormal

Qualitative markers:

  • Libido and morning erections
  • Energy and mood stability
  • Vision (blurring, spots or flashes)
  • Breast tenderness or swelling
  • Leg swelling, chest pain or sudden breathlessness
  • Testicular lumps on self-examination

Emerging Research

  • No active enclomiphene trials: A ClinicalTrials.gov search in October 2026 found no recruiting or active enclomiphene trial, so no new controlled enclomiphene data are expected soon; evidence will come from clomiphene trials and practice cohorts.
  • Prostate-cancer survivors: The 83-man HRT-PC phase II trial will give clomiphene 25 mg to men with persistent low testosterone after androgen deprivation therapy (hormone blockade for prostate cancer), alongside an untreated recovery cohort; primary endpoint testosterone ≥300 ng/dL; not yet recruiting (NCT07882862). Positive: extends the class to older survivors; null: narrows it.
  • Tendon healing: A recruiting phase II trial in 58 patients tests clomiphene with rotator cuff repair, with MRI (magnetic resonance imaging) tendon healing as the endpoint (NCT04944836). Positive: first tissue-level benefit for the class; null: weakens musculoskeletal claims.
  • Completed but unpublished Repros trials: Bone density (NCT01619683, completed 2014), heart-rhythm safety (NCT02117830, completed) and drug interactions (NCT01991327, completed 2014) posted no results; body composition (NCT02651688, completed 2017) posted no lean-mass benefit and smaller weight loss than placebo.
  • Head-to-head with clomiphene: Only retrospective comparisons exist (Saffati 2024, Thomas 2023); a randomized comparison could confirm or erase enclomiphene’s tolerability edge and its price premium.
  • Telehealth real-world cohorts: A 6,999-man cohort from a telehealth company (Menwell) found similar quality-of-life gains with clomiphene or hCG strategies (Clift 2026); comparable enclomiphene data could quantify long-term safety, in either direction.
  • Safety signals: New case reports, such as atrial flutter after dose escalation (Tariq 2026), may strengthen or fade with post-marketing safety monitoring as compounded use grows.

Conclusion

Enclomiphene is an estrogen-blocking oral drug that prompts the brain to signal the testes to make more of their own testosterone. For men whose low testosterone stems from weak brain signaling, often linked to excess weight, the evidence that it raises testosterone into the normal range is consistent, and unlike testosterone itself it generally keeps sperm production going. Whether those higher numbers bring better energy, libido, body composition or blood sugar has not been shown for enclomiphene; borrowed evidence from its parent drug, clomiphene, is mixed.

The main concerns are a minority of men whose sperm counts fall rather than hold steady, smaller weight loss than placebo during dieting in one trial, a blood-clot signal that led European regulators to refuse approval, and estrogen-related, visual and mood effects known mostly from clomiphene. Safety beyond about a year of use is unknown.

The evidence base is thin and lopsided: nearly all controlled trials were run by the company that sought approval, later supportive statements come partly from clinicians tied to companies selling the drug, and no company now has a financial reason to fund large trials on symptoms or long-term safety. The product reaching men today is custom-made by pharmacies, unapproved by regulators and banned in tested sport. For a risk-aware man who wants to keep his own hormone production and fertility intact, enclomiphene is a well-documented way to raise a laboratory number, with its effects on how he feels and its long-term risks still largely uncharted.

Top - Benefits - Risks - Protocol